Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: bupropion-SR Clear all
Completed Phase 1Phase 2 Interventional

A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder

NCT00593099
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 23, 2026, 2:29 AM EDT
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dynamic Measures of Neurochemistry in Mood Disorders

NCT00178828
View directory record Official record
Conditions
Depression
Interventions
sertraline, bupropion
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

NCT00307203
View directory record Official record
Conditions
Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders
Interventions
bupropion SR, Cognitive Behavioral Group Therapy, nicotine replacement therapy
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

NCT00474630
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
53
States / cities
Fairhope, Alabama • Peoria, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy

NCT01286402
View directory record Official record
Conditions
Smoking Cessation
Interventions
Bupropion SR, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Varenicline and Bupropion for Smoking Cessation

NCT00935818
View directory record Official record
Conditions
Smoking
Interventions
Varenicline, placebo, bupropion SR
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
3
States / cities
Minneapolis, Minnesota • Rochester, Minnesota • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 23, 2026, 2:29 AM EDT
Terminated Phase 4 Interventional

Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia

NCT01576640
View directory record Official record
Conditions
Nicotine Dependence, Schizophrenia
Interventions
NRT, Bupropion SR 150mg bid, Relapse Prevention-Oriented Cognitive Behavioral Therapy
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 4 Interventional

Combination Medications vs. Patch Alone for Medically-Ill Smokers

NCT00770666
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine patch, nicotine inhaler, bupropion, Nicotine patch
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 10, 2008 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

NCT00456521
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Placebo, Intensive group lifestyle modification counseling
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combined Pharmaco/Behavior Therapy in Adolescent Smokers

NCT00330187
View directory record Official record
Conditions
Nicotine Dependence, Nicotine Use Disorder
Interventions
Bupropion SR, Contingency Management, Placebo
Drug · Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Bupropion for Smoking Cessation in Pregnancy

NCT01875172
View directory record Official record
Conditions
Smoking Cessation, Pregnancy
Interventions
Bupropion SR, placebo, smoking cessation counseling
Drug · Behavioral
Lead sponsor
Watching Over Mothers & Babies Foundation
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of Bupropion SR and Placebo for Smoking Cessation

NCT00176449
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion SR, Placebo Oral Tablet
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

NCT00865111
View directory record Official record
Conditions
Healthy
Interventions
Bupropion 150 mg Extended-Released Tablet, single dose, Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 23, 2026, 2:29 AM EDT
Active, not recruiting Phase 3 Interventional

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

NCT03996265
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
542
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 335 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers

NCT01048944
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Bupropion SR, Nicotine Patch, Placebo Patch and Placebo Pill
Drug
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 55 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

NCT03045341
View directory record Official record
Conditions
Binge-eating Disorder, Obesity
Interventions
NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

NCT00563563
View directory record Official record
Conditions
Nicotine Dependence, Overweight, Obesity
Interventions
NB32, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 4 Interventional

Dissemination of Tobacco Tactics for Hospitalized Smokers

NCT01309217
View directory record Official record
Conditions
Smoking Cessation
Interventions
Tobacco Tactics Intervention, Usual Care
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Grand Rapids, Michigan • Livonia, Michigan • Muskegon, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 23, 2026, 2:29 AM EDT
Recruiting Phase 4 Interventional

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

NCT04604509
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 2:29 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

NCT00511134
View directory record Official record
Conditions
Insomnia, Nicotine Dependence
Interventions
Eszopiclone, Bupropion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

NCT00129246
View directory record Official record
Conditions
Smoking, Nicotine Dependence
Interventions
Naltrexone, Bupropion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns

NCT02078180
View directory record Official record
Conditions
Depression
Interventions
generic bupropion
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 23, 2026, 2:29 AM EDT